EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity

Gustave Munyurangabo iD, Linlin Zhang iD, Ying Zhou, Peihua Zhang, Xiao Yu, Dou Qu, Dan Yang, Xiaomin Ren, Hongwei Liu, Yonghong Wu, Guangyao Kong iD, Yi Yang iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Gustave Munyurangabo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an…. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Juvenile, Proto-Oncogene Proteins p21(ras), Epigenesis, Genetic, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Research and Development Program of Shaanxi Province of China, Natural Science Foundation of Shaanxi Province of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Juvenile myelomonocytic leukaemia (JMML) primarily stems from the Rat Sarcoma (RAS)/Extracellular Signal‐Regulated Kinase (ERK) pathway mutations, and currently, there are no effective regimens against JMML, yet various studies have highlighted the importance of deciphering secondary genetic and/or epigenetic alterations in pursuit of treatments. Setd2 ‐mediated‐H3K36me3 participates in myriad biological functions and primarily serves as a tumour suppressor gene in carcinogenesis. However, little is known about the synergism between Setd2 deficiency and Kras mutation during JMML onset and progression. Herein, we reveal that Kras ‐mutant JMML possesses a lower H3K36 trimethylation mark, and Setd2 ablation in the KrasG12D/+‐mediated JMML model shortens the disease latency. Phenotypically, Setd2 deficiency perturbs myeloid progenitor cell differentiation in KrasG12D/+ mutant mice and confers enhanced proliferative ability. Furthermore, the functional studies demonstrate that concurrent Setd2 depletion and Kras mutation expression promote cell cycle progression and enhance colony‐forming ability while escaping apoptosis. Mechanistically, myeloid progenitor cells derived from Setd2−/−; KrasG12D/+ co‐mutant mice hyperactivate ERK1/2 by reducing the H3K36me3 level on the Dusp1 gene body. Interestingly, a combination of mitogen‐activated protein kinase (MEK) and Setd2 inhibitors effectively inhibits the malignant growth of human and mouse leukaemia cell lines in vitro. Hence, the current project provides strong concepts for targeting ERK signalling and Setd2 in oncogenic RAS‐mediated leukaemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, JuvenileProto-Oncogene Proteins p21(ras)Epigenesis, GeneticHistone-Lysine N-MethyltransferaseMutationProtein Kinase InhibitorsAnimalsMiceHumansMAP Kinase Signaling System

Stichwörter der Autor:innen

Dusp1MEK inhibitorRAS mutationSetd2juvenile myelomonocytic leukaemia

Substanzen

Proto-Oncogene Proteins p21(ras)Histone-Lysine N-MethyltransferaseProtein Kinase InhibitorsHras protein, mouseSETD2 protein, mouse

Autor:innen und Institutionen

  • Department of Haematology, National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
  • Center for Tumor and Immunology, The Precision Medical Institute, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
  • College of Medical Technology, Xi'an Medical University, Shaanxi, People's Republic of China.

ORCID-Profile: Gustave Munyurangabo, Linlin Zhang, Guangyao Kong, Yi Yang

Förderung

  • Key Research and Development Program of Shaanxi Province of China
  • Natural Science Foundation of Shaanxi Province of China
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shaanxi Fundamental Science Research Project for Chemistry and Biology

Zitieren

APA

Munyurangabo, G., Zhang, L., Zhou, Y., Zhang, P., Yu, X., Qu, D., Yang, D., Ren, X., Liu, H., Wu, Y., Kong, G., & Yang, Y. (2025). Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity. British Journal of Haematology. https://doi.org/10.1111/bjh.70060

Vancouver

Munyurangabo G, Zhang L, Zhou Y, Zhang P, Yu X, Qu D, et al. Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity. British Journal of Haematology. 2025. doi:10.1111/bjh.70060

BibTeX
@article{Munyurangabo2025,
  author = {Munyurangabo, Gustave and Zhang, Linlin and Zhou, Ying and Zhang, Peihua and Yu, Xiao and Qu, Dou and Yang, Dan and Ren, Xiaomin and Liu, Hongwei and Wu, Yonghong and Kong, Guangyao and Yang, Yi},
  title = {Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70060}
}
Kostenlos starten →